Alkermes (ALKS) EPS (Basic) (2010 - 2026)

Alkermes (ALKS) posted quarterly EPS (Basic) of $0.0 for Q2 2026, up 100.78% quarter-over-quarter from -$0.4 in Q1 2026.

Alkermes (ALKS) EPS (Basic) (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported EPS (Basic) for 17 consecutive years, with $0.0 the latest figure, recorded in Q2 2026.

In Q2 2026, EPS (Basic) changed N/A year-over-year to $0.0; the TTM figure through Jun 2026 stood at -$0.1 (down 2667.36% YoY), while the FY2025 annual figure was $1.47, up 4291.28% from the prior year.
EPS (Basic) climbed to $0.0 in Q2 2026 per ALKS's latest filing, from -$0.4 in the prior quarter.
Across five years, EPS (Basic) topped out at $0.54 in Q4 2022 and bottomed at -$0.4 in Q1 2026.
Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of -$0.18 in 2022.
Annual changes were most pronounced in 2022 — EPS (Basic) tumbled 1351.28% — and 2025, when it soared 4328.36%.
Alkermes' EPS (Basic) stood at $0.54 in 2022, then tumbled by 145.83% to -$0.25 in 2023, then surged by 102.75% to $0.01 in 2024, then jumped by 4328.36% to $0.3 in 2025, then tumbled by 98.95% to $0.0 in 2026.
Business Quant data shows ALKS's EPS (Basic) at $0.0 in Q2 2026, -$0.4 in Q1 2026, and $0.3 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-0.49
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	2.07
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	0.45
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	7.82
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-0.10
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	1.43
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	0.11
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	0.00

Download Data